Impact of comprehensive genomic profiling (CGP) on physician treatment recommendations in metastatic solid tumor pts who previously failed at least two standard therapies: A prospective study.

e22054 Background: Comprehensive genomic profiling (CGP) of routinely fixed tissue from pts with advanced solid tumors can uncover tumor specific gene alterations. Foundation Medicine has developed a CLIA-certified, CAP-accredited test to simultaneously characterize all 4 classes of genomic alterations in 236 (originally 182) cancer genes. Primary study objective was to determine how often physician treatment decisions for pts with advanced cancer would be modified after reviewing results of this test. Methods: This was a prospective, single-center investigator initiated trial in pts with metastatic solid tumors. Pts with disease progression after at least one treatment regimen, determined to be likely to fail current treatment (2ndline or more) within 6 months and an expected survival of ≥ 3 months were eligible. Pts signed protocol informed consent and tumor tissue was sent for CGP. Physicians completed a questionnaire indicating their choice of next appropriate treatment for pts progressing on current ...